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Vorinostat (NSC# 701852) in Patients with Relapsed
Non-small Cell Lung Cancer
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Kathleen Schell, MS,* Michael S. Huie, MD,* David L. Groteluschen, MD,‡ Sarah M. Marcotte, MS,*
Courtney M. Hallahan, BS,* Hilary R. Weeks, BS,* George Wilding, MD,*
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Introduction: Vorinostat is a small molecule inhibitor of histone
deacetylase, and has shown preclinical activity in non-small cell
lung cancer (NSCLC).
Methods: Patients with relapsed NSCLC were eligible. Patients
received oral vorinostat, 400 mg daily. The primary objective
was response rate, with the goal of at least one responder in the
first 14 evaluable patients, according to the two-stage minimax
design. Secondary objectives included time to progression (TTP),
overall survival (OS), and safety.
Results: Sixteen patients enrolled from January 2006 to April 2007.
The median age was 59.5 years. Thirteen patients were female. Two
patients were not evaluable for response due to progressive disease
within Cycle 1. No objective antitumor responses were seen in the
14 evaluable patients. Eight patients experienced stable disease (me-
dian 3.7 months, range 1.4–19.4). Median TTP was 2.3 months (range
0.9–19.4 months), median OS was 7.1 months (range 1.4–30.0
months), and estimated 1 year OS rate was 19% (SE 10%). One
patient died on study from an acute ischemic stroke; this event was
deemed possibly related to treatment. Grade 3/4 adverse events
possibly related to vorinostat included neutropenia, lymphopenia,
fatigue, pulmonary embolus/deep vein thrombosis, dehydration,
elevated alkaline phosphatase, and hypokalemia.
Conclusions: No objective antitumor activity was detected with
single agent vorinostat in this setting; however, it yields TTP in
relapsed NSCLC similar to that of other targeted agents. Further
studies in NSCLC should focus on combining vorinostat with other
antitumor agents.
Key Words: Non-small cell lung cancer, Relapsed disease, Histone
deacetylase inhibitors, Phase II.
(J Thorac Oncol. 2009;4: 522–526)
Treatment of relapsed non-small cell lung cancer (NSCLC)remains discouraging. Results from clinical trials yield
median survivals that range from 6 to 9 months, and rates of
toxicities, particularly with the use of cytotoxic agents, are
not negligible.1–4 Investigation of more effective, or at least
less toxic, agents and combinations remains paramount.
Histone deacetylases (HDACs) represent an emerging
therapeutic target in NSCLC and other malignancies since the
extent of histone acetylation impacts gene expression, includ-
ing those genes involved in the prosurvival signaling cas-
cades, regulation of apoptosis, and control of the cell cycle.5–7
Histone deacetylase inhibitors effect cell death by activating
apoptotic pathways, mitotic failure, or autophagic cell
death.5,8,9 Normal cells are relatively resistant to cell death
induced by HDAC inhibitors. This specificity may be related
to protection from generation of reactive oxygen species
found in the normal cell. As such, HDAC inhibitors may offer
an appealing therapeutic index in cancer therapy.10
Vorinostat (suberoylanilide hydroxamic acid, SAHA,
Zolinza™, NSC# 701852) is a small molecule inhibitor of
class I and II HDACs. It has yielded antiproliferative and
pro-apoptotic results in multiple cancer cell lines (including
NSCLC) and xenograft mouse models.11–13 Preclinical stud-
ies using NSCLC and other cell lines confirmed the ability of
vorinostat to enhance the cytotoxicity of radiation, targeted
agents, and traditional DNA-directed chemotherapeutics.14–16
Phase I trials with oral vorinostat identified the maxi-
mum tolerated dose to be 400 mg once daily or 200 mg twice
daily in patients with solid tumors or hematologic malignan-
cies, or 300 mg twice daily for three consecutive days per
week for patients with solid tumors.17,18 Dose limiting toxic-
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ities included anorexia, dehydration, diarrhea, and fatigue.
Drug-related adverse events were constitutional (fatigue), gas-
trointestinal (anorexia, diarrhea, nausea, and vomiting), meta-
bolic (hyperglycemia and hypocalcemia), and hematologic
(thrombocytopenia, anemia, and some neutropenia). Antitumor
activity was seen in patients with Hodgkin’s and non-Hodgkin’s
lymphoma, mesothelioma, differentiated thyroid cancer, bladder
cancer, and laryngeal cancer. Accumulation of acetylated his-
tones H3 and H4 was demonstrated 4 hours after treatment with
vorinostat in peripheral blood mononuclear cells and in three of
five paired tumor biopsies.17,18
Two schedules of vorninostat (400 mg once daily for 14
days and 300 mg twice daily for 7 days) were tolerated well
when combined with carboplatin and paclitaxel.19 This phase
I combination study yielded surprisingly robust antitumor
activity in patients with advanced NSCLC: 10 of 19 patients
obtained a partial response.19 Vorinostat obtained Food and
Drug Administration approval in refractory cutaneous T
cell lymphoma resulting from a nearly 30% response rate
(RR).20,21 Disease activity has also been seen in a phase II
trial of mesothelioma, such that a randomized trial is under-
way for patients who have progressed through pemetrexed.22
Phase II trials in advanced ovarian cancer, head and neck
cancers, and relapsed diffuse large-B-cell lymphoma were
negative.23–25
The objective of our multicenter phase II trial was to
establish the single agent activity of vorinostat in the second
line setting of advanced NSCLC. Additional objectives in-
cluded examining the safety profile of vorinostat in this
population, and estimating survival of treated patients.
PATIENTS AND METHODS
Patient Selection
Patients at least 18 years of age with pathologically
confirmed advanced (stage IIIB with pleural or pericardial
effusion, stage IV, or recurrent) NSCLC whose disease had
progressed during or after treatment with no more than one
prior cytotoxic combination chemotherapy regimen and who
gave informed consent according to institutional and Food
and Drug Administration guidelines were eligible for this
study provided that the following criteria were met: Eastern
Cooperative Oncology Group performance status of 0 or 1;
brain metastases, if present, must have been clinically stable
after treatment with surgery and/or radiotherapy; adequate
bone marrow, liver and renal function; life expectancy of at
least 3 months; measureable disease per RECIST criteria;
peripheral neuropathy less than or equal to grade 1 per the
National Cancer Institute (NCI) Common Terminology Cri-
teria for Adverse Events version 3.0; no prior therapy with
valproic acid within 2 weeks of enrollment; no treatment with
chemotherapy or radiotherapy within 3 weeks of enrollment;
no other active malignancy in the past 5 years except non-
melanoma skin cancer; absence of HIV positivity; and no
uncontrolled intercurrent illness that would limit compliance
with study requirements. This protocol was approved through
institutional ethics review boards of each participating center
in the Wisconsin Oncology Network.
Treatment Plan
Vorinotstat (NSC# 701852) was supplied by the Cancer
Therapy Evaluation Program of the National Cancer Institute
as gelatin capsules containing either 100 mg or 300 mg of
drug. Vorinostat was self-administered with food, continu-
ously, at 400 mg orally, once daily, in a 21 day cycle.
Treatment was continued until disease progression, unaccept-
able toxicity, or withdrawal of consent. The vorinostat dose
was reduced according to prestudy-defined adverse event
criteria to 400 mg or 300 mg once daily on days 1 to 14 of the
21 day cycle. Patients who required more than two dose
reductions due to toxicity were removed from the study. All
toxicities (except alopecia) must have resolved to grade 1 or
less before the start of the next cycle. All dose reductions
were permanent. Patients completed a standardized capsule
calendar to document treatment compliance.
Disease Assessment
The objective antitumor RR was determined using
computed tomography imaging at baseline and after every
other cycle of treatment. Bone scans and brain imaging were
performed only if clinically indicated. Additional baseline
assessment included a history and physical, complete blood
count, comprehensive chemistry panel, Eastern Cooperative
Oncology Group performance status, and an electrocardio-
gram if clinically indicated.
Statistical Considerations
The primary end point of this study was the overall
confirmed objective RR, defined as the percentage of patients
experiencing complete responses (CRs) and partial responses
(PRs) per RECIST criteria. Secondary objectives included
time to disease progression (TTP), overall survival (OS), the
1-year survival rate, and safety. All patients were evaluable
for survival and toxicity assessments per the NCI Common
Terminology Criteria for Adverse Events version 3.0. Pa-
tients must have completed one cycle of therapy to be
evaluable for response.
A two-stage minimax design was used to allow the
possibility of early stopping due to lack of efficacy. It was
assumed that a true RR of less than 5% would not warrant
further study of vorinostat treatment in this setting. It was
also assumed that a RR of at least 20% would be considered
promising for further evaluation. In the first stage, 14 evalu-
able patients were to be accrued. If no response was observed,
then accrual would be stopped with the conclusion that
vorinostat treatment was not promising for further study. If at
least one response was observed in the first 14 patients, then
an additional nine patients were to be accrued during the
second stage of the study. The probability of falsely declaring
the regimen with a 5% response probability as warranting
further study was 10% (type I error), and the probability of
correctly declaring the regimen with a 20% response proba-
bility as warranting further study was 85%.
Categorical variables were summarized by frequencies
and percentages, while continuous variables were summa-
rized in terms of medians and ranges. Overall survival, TTP
and duration of stable disease (SD) were analyzed using the
Kaplan-Meier methodology.
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The University of Wisconsin Paul P. Carbone Compre-
hensive Cancer Center (UWCCC) Data and Safety Monitoring
Committee was responsible for monitoring data quality and
patient safety according to UWCCC guidelines. In addition,
each patient’s treatment was reviewed weekly by the UWCCC
Lung Cancer Research Disease Oriented Working Group.
RESULTS
Patient Characteristics
A total of 16 patients were enrolled between January
2006 and April 2007 at three participating sites. Table 1
displays the patient demographics. Eighty-one percent of the
patients were female. Most patients experienced SD from
their prior treatment. All patients were evaluable for toxicity
and survival assessments, including TTP. Two patients were
not evaluable for response due to not completing one cycle of
treatment, both due to progressive disease. The median fol-
low-up is 7.1 months (range 1.4–27).
Treatment
Treatment compliance was calculated as the percentage
of vorinostat taken each cycle, based upon study drug ac-
countability (i.e., capsules returned each cycle). Compliance
with vorinostat was good, at 97.4%. The median number of
cycles administered was 3 (range 1–27).
Toxicities
Table 2 lists grade 2, 3, and 4 toxicities at least possibly
related to treatment.
One patient experienced an acute ischemic stroke and
died while on study; this event was deemed possibly related
to treatment with vorinostat. The patient had no prior history
of hypertension or prior thromboembolic events. She toler-
ated her first cycle of vorinostat without complication. During
the first week of cycle 2 of treatment, she experienced
confusion, headaches, and aphasia. Magnetic resonance im-
aging of the brain detected an acute infarction in the distri-
bution of the right middle cerebral artery, as well as new
evidence of leptomeningeal and parenchymal brain metasta-
ses. She was hospitalized and evaluated by neurologic con-
sultation, who felt that her symptoms were related to her
ischemic infarction. The family elected to pursue supportive
care and the patient died within 2 weeks.
Grade 4 toxicities attributed as at least possibly related
to treatment included two patients with pulmonary emboli
and one episode of neutropenia. Grade 3 toxicities attributed
as at least possibly related to treatment found in at least two
patients included three occurrences of asymptomatic lym-
phopenia and two episodes of fatigue. Three patients had
their treatment delayed due to toxicity not resolving to grade
1 or less prior to the start of the next cycle.
Three patients discontinued treatment due to adverse
events experienced while on study. One patient came off study
due to dyspnea from a pulmonary embolism experienced fol-
lowing two cycles of vorinostat. Her computed tomography scan
performed 30 days after stopping treatment showed progressive
disease. A second patient was taken off study following four
cycles of treatment. She had stable disease but unfortunately
experienced multiple injuries from a life-threatening motor ve-
hicle accident. Lastly, a third patient developed delirium after
completing seven cycles of vorinostat. This patient also had
stable disease at the time. A neurologic consultation diagnosed
the patient with Alzheimer’s disease, and she was started on
donepezil. Two additional patients had their vorinostat dose
TABLE 1. Patient Demographics
Total enrolled 16
Patients evaluable for efficacy 14
Males/females 3/13
Median age (range) 59.5 yr (47–79 yr)
ECOG PS 0/1 10/6
Histology
Adenocarcinoma 6
Bronchoalveolar carcinoma 3
NSCLC NOS 5
Squamous cell 1
Large cell 1
Prior treatment
1 prior chemotherapy regimen 15
1 prior erlotinib regimen 1
Median time since prior treatment 2.7 mo (0.2–78.5 mo)
Best response to prior treatment
Partial response 1
Stable disease 12
Progressive disease 3
ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC,
non-small cell lung cancer.
TABLE 2. Grade 2, 3, and 4 Toxicities at Least Possibly
Related to Treatment
Toxicity Grade No. of Patients
Cerebrovascular accident 5 1
Pulmonary embolism 4 2
Neutropenia 3/4 1/1
Deep vein thrombosis 3 1
Lymphopenia 3 3
Fatigue 3 2
Dehydration 3 1
Elevated alkaline phos 3 1
Hypokalemia 3 1
Neutropenia 4 1
3 1
2 2
Fatigue 3 2
2 2
Hyperglycemia 2 5
Lymphopenia 2 3
Diarrhea 2 2
Anemia 2 1
Anorexia 2 1
Neuropathy–motor 2 1
Palpatations 2 1
Pneumonia 2 1
Thrombocytopenia 2 1
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reduced due to grade 3 toxicity (asymptomatic lymphopenia and
fatigue) possibly related to treatment.
Treatment Efficacy
No objective antitumor responses were seen in the 14
evaluable patients. Over half the patients (8 patients, 57%)
experienced SD as their best response to treatment, with a
median duration of 3.7 months (range 1.4–19.4 months). Two
patients (12.5%) were not evaluable for response due to not
completing one cycle of treatment, both due to progressive
disease, and were therefore classified as nonresponders. Me-
dian TTP for the study population measured 2.3 months
(range 0.9–19.4 months). Median OS was 7.1 months (range
1.4–30 months), and, to date, 15 patients have died. The
estimated 1 year OS rate was 19% (standard error 10%).
Thirteen patients discontinued treatment due to disease pro-
gression, and three due to toxicity (one of which, a pulmonary
embolism, was possibly treatment related). Of the seven
patients who received subsequent systemic therapy, five were
treated with pemetrexed and two received erlotinib.
DISCUSSION
This multicenter, open-label, nonrandomized single-arm
phase II study was conducted based upon the biologic rationale
of HDAC inhibitors as cancer therapeutics, and due to the
efficacy of vorinostat seen in preclinical NSCLC models. Un-
fortunately, none of our patients experienced an objective re-
sponse to treatment per RECIST criteria. Despite this, our rate of
stable disease, median time to disease progression, and OS were
commensurate with results seen using other agents in this set-
ting.1–4 It may be that RECIST criteria are not the best means to
gauge the efficacy of vorinostat, or other targeted agents, and
that patients may still accrue clinical benefit from nonprogres-
sive disease.26,27 As such, low rates of early progressive disease
may more accurately describe the clinical performance of this
class of therapeutics.28 However, any consideration of our effi-
cacy with vorinostat must take into account that 81% of our
patients were female, a population with improved efficacy out-
comes in NSCLC, compared with men, irrespective of treatment.29
The low rate of antitumor response with single agent
vorinostat may have been expected, since it was suggested
that vorinostat be classified as a biologic response modifier,
rather than as a traditional cytotoxic drug.23 Combining
HDAC inhibitors in preclinical models with either cytotoxic
or targeted anticancer agents has yielded synergistic re-
sults.5,16,30,31 Clinically, this potentiation was suggested by the
surprisingly high RR (53% in NSCLC patients) seen when
carboplatin and paclitaxel were combined with vorinostat.19
Sensitization to paclitaxel may be related to the ability of HDAC
inhibitors to stabilize microtubules.32 Further clinical explora-
tion of this modulatory capability of vorinostat will result from
the outcomes of two large clinical trials presently underway that
randomize patients with advanced NSCLC to carboplatin and
paclitaxel with or without vorinostat.
The range of toxicities in this trial mirrored that seen
with other clinical experiences with vorinostat, including
primarily fatigue, dehydration, hyperglycemia, and mild my-
elosuppression.17,22–24 Two prior vorinostat trials in CTCL
reported patients who experienced pulmonary emboli and
deep vein thromboses.20–21 The incidence of thromboembolic
complications in patients with lung cancer is estimated at
10%.33 No association is described in the literature between
histone deacetylase inhibitors and thromboembolism. Not
unexpectedly, two of our patients experienced pulmonary
emboli, both when their disease was very advanced, within a
few weeks of their deaths. A third patient, with no prior
history of thrombosis, was diagnosed with a deep vein throm-
bosis in cycle 3 of treatment when she had stable disease.
Evaluation of any possible association of treatment in ad-
vanced NSCLC with thromboembolic complications is diffi-
cult, but more information will be forthcoming from large
randomized trials of vorinostat in front-line disease.
In addition, one of our patients died during cycle 2 with
an acute ischemic stroke. Olsen et al.21 also reported a patient
with CTCL receiving vorinostat who experienced an isch-
emic stroke and died on day 227. Our patient’s experience is
complicated by her concurrent diagnosis of leptomeningeal
and parenchymal brain metastases. A review of stroke in
cancer patients from Memorial Sloan Kettering found that
30% of those patients carried a diagnosis of lung cancer, and
half of those strokes were “nonembolic,” the category that
included ischemic strokes.34 Recent laboratory data using rat
models with middle cerebral artery occlusion demonstrated
that HDAC inhibitors, including vorinostat, exert a neuropro-
tective effect in this setting, decreasing histone deacetylation
in the brain, reducing infarct size, and in one report, yielding
improved neurofunctional outcomes.35–37 These studies con-
cluded by recommending the study of HDAC inhibitors in
this clinical setting, so any relation between ischemic stroke
and vorinostat in our patient is unclear.
Eighty-one percent of our patients were female. We
believe this disproportionate gender enrollment occurred due
to chance. Accrual to this trial started off briskly (10 patients
enrolled in the first 4 months), but then declined thereafter for
reasons that are not clear. Ironically, only two community
practice sites in our Wisconsin Oncology Network opened
this trial due to the brisk initial accrual at the University of
Wisconsin. It is likely that more sites would have participated
in this trial had the initial enrollment at the University of
Wisconsin not been so rapid.
In conclusion, vorinostat as a single agent in our pa-
tients with relapsed NSCLC did not exert disease activity per
RECIST criteria. Stable disease resulted in over half our
patients, but efficacy conclusions are limited by our small
number of patients and the fact that 81% were female.
Toxicities were similar to other disease studies of vorinostat.
Due to potential capabilities as a biologic response modifier,
vorniostat may prove most beneficial in combination therapy.
A patient with advanced NSCLC experienced a PR when
receiving treatment with vorinostat combined with bor-
tezomib in an NCI-sponsored phase I study at the University
of Wisconsin; as such, and given preclinical evidence sup-
porting this combination, we are developing a phase II study
of these agents to be run through our Wisconsin Oncology
Network.38–40 Additional clinical trials in NSCLC are under-
way combining vorinostat with erlotinib and cytotoxic che-
motherapeutics.
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